If approved, the acquisition would combine two of the leading makers of heart-related devices. The deal will cost Abbott roughly $25 billion.
For Abbott, the acquisition represents a way for the company to enhance its position in the medical devices business and “gain a better negotiating position” with its hospital customers, according to a NASDAQ report.
Both organizations agreed to the partnership in April. They expect the deal to officially close in the fourth quarter.
More articles about transactions and valuations:
Washington Health System, UPMC strike cardiac surgery partnership
McLeod Heath to acquire Clarendon Health System
Yale New Haven, Lawrence & Memorial deal faces public scrutiny
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
